Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Moderna Inc (MRNA) is a leading biotechnology business based in the US. It opened the day at $123.67 after a previous close of $120.99. During the day the price has varied from a low of $123.50 to a high of $126.41. The latest price was $125.67 (25 minute delay). Moderna is listed on the NASDAQ and employs 3,400 staff. All prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Open | $123.67 |
|---|---|
| High | $126.41 |
| Low | $123.50 |
| Close | $125.67 |
| Previous close | $120.99 |
| Change | $4.68 |
| Change % | 3.8681% |
| Volume | 3,383,446 |
| 52-week range | $115.03 - $376.65 |
|---|---|
| 50-day moving average | $146.84 |
| 200-day moving average | $159.98 |
| Wall St. target price | $217.86 |
| PE ratio | 3.8059 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $31.79 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $125.67 from 2022-10-03
| 1 week (2022-09-28) | 2.88% |
|---|---|
| 1 month (2022-09-02) | -9.31% |
| 3 months (2022-07-05) | -19.20% |
| 6 months (2022-04-01) | N/A |
| 1 year (2021-10-04) | -61.43% |
|---|---|
| 2 years (2020-10-05) | 74.66% |
| 3 years (2019-10-04) | 710.25% |
| 5 years (2017-10-01) | N/A |
Valuing Moderna stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Moderna's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Moderna's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Moderna shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Moderna's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $15.9 billion.
The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $23 billion |
|---|---|
| Operating margin TTM | 68.02% |
| Gross profit TTM | $13.9 billion |
| Return on assets TTM | 46.34% |
| Return on equity TTM | 113.86% |
| Profit margin | 61.12% |
| Book value | $45.88 |
| Market capitalisation | $47.3 billion |
TTM: trailing 12 months
We're not expecting Moderna to pay a dividend over the next 12 months.
Over the last 12 months, Moderna's shares have ranged in value from as little as $115.03 up to $376.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.6854. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Moderna, Inc. , a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co. , Inc. ; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
